Cytosorbents Corp
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
CTSO$5.83+21.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · At December 31, | ||||||
| · 2024 · 2023 | ||||||
| · · · As restated | ||||||
| ASSETS · · · | ||||||
| Current Assets: · · · | ||||||
| Cash and cash equivalents | | $3,279,926 | | $14,131,137 | ||
| Restricted cash, current | | | 5,000,000 | | | — |
| Grants and accounts receivable, net of allowances of $157,701 and $49,663 at December 31, 2024 and 2023, respectively | | 7,319,597 | | 6,057,072 | ||
| Inventories | | 2,732,907 | | 3,375,817 | ||
| Prepaid expenses and other current assets | | 3,270,812 | | 1,834,485 | ||
| Total current assets | | 21,603,242 | | 25,398,511 | ||
| | | | | | ||
| Property and equipment - net | | 9,002,383 | | 10,056,354 | ||
| Restricted cash | | | 1,483,958 | | | 1,483,958 |
| Right-of-use asset | | | 11,511,236 | | | 12,058,896 |
| Other assets | | 3,770,681 | | 3,958,603 | ||
| Total Assets | | $47,371,500 | | $52,956,322 | ||
| | | | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | ||||
| Current Liabilities: | | | ||||
| Accounts payable | | $3,339,885 | | $3,802,170 | ||
| Accrued expenses and other current liabilities | | 6,031,670 | | 7,359,786 | ||
| Lease liability – current portion | | | 452,688 | | | 373,636 |
| Current maturities of long-term debt | | | — | | | 2,500,000 |
| Total current liabilities | | 9,824,243 | | 14,035,592 | ||
| Lease liability, net of current portion | | | 12,443,971 | | | 12,896,659 |
| Long-term debt, net of current maturities | | 13,996,350 | | 2,542,857 | ||
| Total Liabilities | | 36,264,564 | | 29,475,108 | ||
| | | | ||||
| Commitments and Contingencies | | | | | ||
| Stockholders’ Equity: | | | ||||
| Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023 | | | — | | | — |
| Common Stock, Par Value $0.001, 100,000,000 shares authorized at December 31, 2024 and 2023; and 54,830,146 and 54,240,265 shares issued and outstanding at December 31, 2024 and 2023, respectively | | 54,830 | | 54,240 | ||
| Additional paid-in capital | | 310,808,711 | | 306,187,314 | ||
| Accumulated other comprehensive income | | 4,252,013 | | 529,321 | ||
| Accumulated deficit | | (304,008,618) | | (283,289,661) | ||
| Total stockholders’ equity | | 11,106,936 | | 23,481,214 | ||
| Total Liabilities and Stockholders’ Equity | | $47,371,500 | | $52,956,322 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.